EUVIMEDEUVIMED entdecken
Crossref

Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation

Yusuke Ogata iD, Masumi Bamba, Koichi Bamba, Ryo Hisada, Hiroyuki Nakamura

International Journal of Rheumatic Diseases · 2026

DOI: 10.1111/1756-185x.70551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Yusuke Ogata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Takikawa Municipal Hospital, Takikawa, Hokkaido, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Rheumatoid Factor, Antirheumatic Agents, Cysteine. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Bucillamine is a conventional synthetic disease‐modifying antirheumatic drug that can be used as a methotrexate alternative. However, which patients with rheumatoid arthritis can benefit from bucillamine treatment has not been established.

Methods

Patients who had taken bucillamine and discontinued it in 2021 due to a nationwide supply shortage were included in this study. We followed up these patients regarding arthritis exacerbation after bucillamine discontinuation until March 2025. Baseline clinical patient characteristics were compared between the exacerbation and non‐exacerbation groups.

Results

Thirteen of the 18 patients experienced arthritis exacerbation, whereas five remained exacerbation‐free for up to 48 months. The baseline rheumatoid factor levels were significantly higher in the exacerbation group (49 U/mL) than in the non‐exacerbation group (6 U/mL). Receiver operating characteristic and Kaplan–Meier analyses showed that baseline RF levels ≥ 28 U/mL predicted arthritis exacerbation after bucillamine discontinuation (sensitivity 76.2% and specificity 80.0%).

Conclusion

Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidRheumatoid FactorAntirheumatic AgentsCysteineHumansFemaleBiomarkersMaleDisease ProgressionTime FactorsAgedMiddle AgedTreatment OutcomeTreatment Interruption

Stichwörter der Autor:innen

Japanarthritis exacerbationbucillamineconventional synthetic disease‐modifying antirheumatic drugsrheumatoid arthritisrheumatoid factortreatment discontinuation

Substanzen

bucillamineRheumatoid FactorAntirheumatic AgentsBiomarkersCysteine

Autor:innen und Institutionen

  • Takikawa Municipal Hospital, Takikawa, Hokkaido, Japan.
  • Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.

ORCID-Profile: Yusuke Ogata

Zitieren

APA

Ogata, Y., Bamba, M., Bamba, K., Hisada, R., & Nakamura, H. (2026). Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70551

Vancouver

Ogata Y, Bamba M, Bamba K, Hisada R, Nakamura H. Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70551

BibTeX
@article{Ogata2026,
  author = {Ogata, Yusuke and Bamba, Masumi and Bamba, Koichi and Hisada, Ryo and Nakamura, Hiroyuki},
  title = {Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation},
  journal = {International Journal of Rheumatic Diseases},
  year = {2026},
  doi = {10.1111/1756-185x.70551}
}
Kostenlos starten →